朱五福

江西科技師範大學藥學院教師

朱五福, 男,理學博士,講師 ,碩士生導師,中共黨員 ,江西科技師範大學藥學院教師 研究方向: 抗腫瘤藥物研究與開發、計算機輔助藥物設計

基本介紹

  • 中文名:朱五福
  • 國籍:中國
  • 民族:漢
  • 出生地:中國
  • 職業:江西科技師範大學藥學院教師
  • 畢業院校:哈爾濱商業大學、瀋陽藥科大學
個人簡介,研究方向,學習經歷,科研項目,論文情況,

個人簡介

朱五福, 1985,男,理學博士,講師 ,碩士生導師,中共黨員 ,江西科技師範大學藥學院教師

研究方向

抗腫瘤藥物研究與開發、計算機輔助藥物設計

學習經歷


   工作 2012.7至今 江西科技師範學院 藥學院 教學、科研
碩博連讀 2007.9-2012.6 瀋陽藥科大學 藥物化學
本科 2003.9-2007.6 哈爾濱商業大學 製藥工程

科研項目

1、 國家自然科學基金項目(項目號:81460527,主持)
2、江西省教育廳科技計畫項目(項目號:GJJ13578,主持)
3、江西省自然科學基金項目(項目號:20142BAB215020,主持)
4、江西省高等學校教改項目(項目號:JXJG-13-10-19,主持)
5、國家自然科學基金項目(項目號:21362012,參與)
6、 江西科技師範大學博士科研啟動項目(主持)
7、 國家自然科學基金項目(項目號:21002065;主要參與者)
8、 瀋陽市科技計畫項目(項目號:F10-205-1-65;主要參與者)

論文情況

[1] Zhu W, Sun C, Xu S, Pengwu Zheng* ,et al. Design, synthesis, anticancer activity and docking studies of novel 4-morpholino-7, 8-dihydro-5H-thiopyrano [4, 3-d] pyrimidine derivatives as mTOR inhibitors[J]. Bioorganic & medicinal chemistry, 2014, 22(24): 6746-6754. SCI 2.95
[2] Zhu W, Chen C, Sun C, Pengwu Zheng* , et al. Design, synthesis and docking studies of novel thienopyrimidine derivatives bearing chromone moiety as mTOR/PI3Kα inhibitors[J]. European journal of medicinal chemistry, 2015, 93: 64-73.SCI=3.46
[3] Tang, Q., Zhang, G., Du, X., Zhu, W., Li, R., Lin, H., Zhao, Y.*. Discovery of novel 6, 7-disubstituted-4-phenoxyquinoline derivatives bearing 5-(aminomethylene) pyrimidine-2, 4, 6-trione moiety as c-Met kinase inhibitors. Bioorganic & Medicinal Chemistry,第22卷, 第4期,1236-1249頁,2014 (SCI, IF=2.903)
[4] Wang F, Wang L, Zhao Y, Yi Li, Guanfang Ping, Shu Xiao, Kang Chen, Wufu Zhu et al. A novel small-molecule activator of procaspase-3 induces apoptosis in cancer cells and reduces tumor growth in human breast, liver and gallbladder cancer xenografts[J]. Molecular oncology, 2014. (IF=5.98)
[5] Wufu Zhu, Yajing Liu, Xin Zhai, Xiao Wang, Yan Zhu, Di Wu, Hongyu Zhou, Ping Gong, Yanfang Zhao*,Design, synthesis and 3D-QSAR analysis of novel 2-hydrazinyl-4-morpholinothieno [3,2-d]pyrimidine derivatives as potential antitumor agents,European Journal of Medicinal Chemistry, 第57卷,162-175頁,2012 (SCI, IF=3.346)
[6] Wufu Zhu, Yajing Liu, Yanfang Zhao, Haiyan Wang, Li Tan, Weijie Fan and Ping Gong*,Synthesis and biological evaluation of novel 6-hydrazinyl-2,4-bismorpholino pyrimidine and 1,3,5-triazine derivatives as potential antitumor agents,Archiv der Pharmazie, Chemistry in life sciences,第345卷,第10期, 812-821頁,2012 (SCI, IF=1.708)
[7] Wufu Zhu , Xin Zhai, Qiangqiang Fu, Fei Guo, Mei Bai, Jianqiang Wang, Haiyan Wang and Ping Gong*,Design, synthesis and anticancer activity of 4-morpholinothieno[3,2-d]pyrimidine derivatives bearing arylmethylene hydrazine moiety,Chemical & Pharmaceutical Bulletin,第60卷,第8期,1037-1045頁,2012 (SCI, IF=1.592)
[8] Wu Fu Zhu, Xin Zhai, Sai Li, Yun Yun Cao, Ping Gong, Ya Jing Liu*,Synthesis and cytotoxic activity of novel 2,6-disubstituted-4-morpholinothieno[3,2-d]pyrimidines as potent anti-tumor agents,Chinese Chemical Letters,第23卷,第6期,703-706頁,2012 (SCI, IF=0.978)
[9] Wufu Zhu*, Chunjiang Wu, Shan Xu, Wei Li, Haihong Fang, Zhichao Chen, Xuhuang Tu, and Pengwu Zheng*,Design, Synthesis, and Biological Evaluation of Sorafenib Analogs Bearing a Sulfonylurea Unit as Novel VEGFR2 Kinase Inhibitors[J], Advanced Materials Research Vols. 989-994 (2014), 1048-1051頁.
[10] Chengyu Sun, Chen Chen , Chunjiang Wu, Pengwu Zheng and Wufu Zhu*, Design, Synthesis and Anticancer Activity of 4-Morpholinothieno[3,2-d]-pyrimidine Derivatives Bearing Chromone Moiety[J], Advanced Materials Research Vols. 989-994 (2014), 568-571頁.
[11] Chen Chen, Chengyu Sun, Shan Xu, YuanbiaoTu, Pengwu Zheng, Wufu Zhu*, Synthesis Of One Novel Thieno[2,3-D]Pyrimidine Derivative Bearing A Sulfonylurea Moiety[J], Advanced Materials Research Vols. 989-994 (2014), 577-580頁.
[12] Chunjiang Wu, Chen Chen, Chengyu Sun, Fei Lei, Haihong Fang, Pengwu Zheng, Rong Luo, Wufu Zhu*, Synthesis Of Substituted Ethyl Argiosulfonylcarbamates[J], Advanced Materials Research Vols. 989-994 (2014), 574-576頁.
[13] 武春江,陳志超,朱五福*,對甲苯磺酸索拉非尼的合成路線綜述,精細化工中間體,第44卷,第4期, 8-12頁,2014.
[14] 陳晨,塗許煌,徐孟澤,鄭鵬武,朱五福*, 2-氨基-5-溴-3 -嗎琳-4-基吡嗪的合成, 精細化工,第31卷,第8期
[15] 孫成鈺,武春江,朱五福*,利拉利汀合成路線圖解,中國新藥雜誌,第23卷,第10卷,1197-1200,2014.
[16] 朱五福,徐珊,鄭鵬武,劉乾,宮平*,PI3K抑制劑GDC-0941的合成,中國新藥雜誌, 第22卷,第11期,1325-1344頁,2013.
[17] 徐珊,朱五福*,鄭鵬武,吳英良,2-氨基-5溴煙醛的合成,精細化工中間體, 第43卷,第3期, 26-28頁,2013.
[18] 朱五福,王海燕,曹云云,白玫,宮平*,1H-吲唑-3-甲醛的簡便合成,化學試劑,第34卷,第3期,287-288頁,2012 (核心).
[19] 朱五福,王碩冰,唐啟東,果秋婷,宮平*,小分子端粒酶抑制劑的研究進展,中國藥物化學雜誌,第21卷,第3期,236-244頁,2011
[20] 朱五福,宮平*,Carglumic acid (Carbaglu),中國藥物化學雜誌,第20卷,第4期, 330-330頁,2010
[21] 朱五福,王海燕,宮平*,依諾格雷合成路線圖解,中國藥物化學雜誌,第22卷,第4期,330-333頁,2012
[22] Shuobing Wang, Yanfang Zhao, Wufu Zhu, Ying Liu, Kaixing Guo, Ping Gong*,Synthesis and anticancer activity of indolin-2-one derivatives bearing 4-thiazolidinone moiety,Archiv der Pharmazie, Chemistry in life sciences,第345卷, 第1期,73-80頁,2012 (SCI, IF=1.708)
[23] Lijun XIE, Xin ZHAI, Lixiang REN, Haiyan MENG, Chun LIU, Wufu ZHU, Yanfang ZHAO*,Design, synthesis and antitumor activity of novel artemisinin derivatives using hybrid approach,Chemical & Pharmaceutical Bulletin,第59卷,第8期,984-990頁,2011 (SCI, IF=1.592)
[24] LI Yang-Xiong,ZHAI Xin,WeiKe Liao, ZHU Wu-fu, Gong Ping*,Design, synthesis and biological evaluation of new rhodacyanine analogues as potential antitumor agents,Chinese Chemical Letters,第23卷,第4期,415-418頁,2012 (SCI, IF=0.978)
[25] 劉海龍,朱五福,王建強,王曉,宮平*,抗腫瘤藥linfinib的合成,中國藥物化學雜誌,第 22卷,第1期,26-28,32頁,2012
[26] 楊智慧,朱五福,王建強,郭飛,付強強,宮平*,鹽酸帕唑帕尼的工藝改進,精細化工中間體,第41卷,第4期,46-48頁,2011
[27] 袁秋慧,唐啟東,柴雨柱,朱五福,果秋婷,宮平*,依諾格雷工藝研究,中國藥物化學雜誌,第22卷,第4期,286-289頁,2012
[28] 曹云云,朱五福,祝研,宮平*,6-取代芳腙基-2,4-雙嗎啉嘧啶及三嗪類衍生物的合成與抗腫瘤活性研究,中國藥物化學雜誌,第23卷,第1期,8-14頁,2013
〖申請專利〗
[1] 朱五福;鄭鵬武;陳晨;徐珊;孫成鈺;武春江;塗其冬. 含色酮腙結構的噻吩並嘧啶類化合物的製備及套用. 2014.5.21, CN103980287A
[2] 朱五福,鄭鵬武等.含芳腙結構的雜環並嘧啶類化合物的製備及套用.201410336092.0
[3] 鄭鵬武,朱五福,武春江,徐珊,孫成鈺,陳晨,陳志超,徐夢澤. 含磺醯脲結構的索拉非尼衍生物的製備及套用. 201410214703.4
[4] GONG, Ping. ZHAO, Yanfang; LIU, Yajing; ZHAI, Xin; LI, Sai; ZHU, Wufu; QIN, Mingze;,QUINOLINE AND CINNOLINE COMPOUNDS AND USE THEREOF,2013-7-4,WO,2013/097280A1.
[5] 宮平,趙燕芳,翟鑫,劉亞婧,朱五福, 新型噻吩並[3,2-d]嘧啶類化合物,2012-08-22,中國,CN102643272
[6] 宮平,劉亞婧,趙燕芳,朱五福,嘧啶及三嗪類化合物的製備方法和套用,2012-9-12,中國,CN102659765

相關詞條

熱門詞條

聯絡我們